Avise® lupus test demonstrates statistically significant clinical utility in achieving a definitive sle diagnosis and positively impacts treatment decisions

San diego, july 13, 2021 (globe newswire) -- exagen inc. (nasdaq: xgn), a leading provider of autoimmune testing solutions, announced today the publication of their latest clinical utility study in lupus & science medicine, found here: https://lupus.bmj.com/content/8/1/e000528.full. this multi-center study demonstrated that the avise lupus test helped increase confidence in ruling-in and ruling-out systemic lupus erythematosus (sle) in patients suspected of this disease and informed appropriate treatment decisions.
XGN Ratings Summary
XGN Quant Ranking